CLINICAL TRIALS PROFILE FOR BIOTHRAX
✉ Email this page to a colleague
All Clinical Trials for BIOTHRAX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01263691 ↗ | Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults | Completed | Department of Health and Human Services | Phase 1 | 2010-12-01 | The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity. |
| NCT01263691 ↗ | Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 2010-12-01 | The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity. |
| NCT01263691 ↗ | Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults | Completed | Emergent BioSolutions | Phase 1 | 2010-12-01 | The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity. |
| NCT01753115 ↗ | Ciprofloxacin BioThrax Co-Administration Study | Completed | Department of Health and Human Services | Phase 2 | 2012-12-01 | The purpose of this clinical trial is to determine whether there is any effect on the antibiotic, ciprofloxacin when taken before and after administration of a 3-dose series of BioThrax® (Anthrax Vaccine Adsorbed or AVA). This study will be conducted in the United States (US) in 154 healthy male and female volunteer subjects ages 18 to 45. The duration of study participation for each subject will be approximately 76 days (approximately 2.5 months) |
| NCT01753115 ↗ | Ciprofloxacin BioThrax Co-Administration Study | Completed | Emergent BioSolutions | Phase 2 | 2012-12-01 | The purpose of this clinical trial is to determine whether there is any effect on the antibiotic, ciprofloxacin when taken before and after administration of a 3-dose series of BioThrax® (Anthrax Vaccine Adsorbed or AVA). This study will be conducted in the United States (US) in 154 healthy male and female volunteer subjects ages 18 to 45. The duration of study participation for each subject will be approximately 76 days (approximately 2.5 months) |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BIOTHRAX
Condition Name
Clinical Trial Locations for BIOTHRAX
Trials by Country
Clinical Trial Progress for BIOTHRAX
Clinical Trial Phase
Clinical Trial Sponsors for BIOTHRAX
Sponsor Name
